ReviewFrontiers in oncology2021
The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions From Routine Practice.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Histopathological Differences Between De Novo and Nevus-Associated Melanoma.Journal of clinical medicine · 2026Article
- [Melanocytic nevi in focus : Clinical interpretation, histopathological criteria, and practice-oriented management].Dermatologie (Heidelberg, Germany) · 2026Article
- From dermatopathology to the courtroom-The promise of cutaneous molecular biomarkers.Frontiers in medicine · 2026Article
- Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma.Journal for immunotherapy of cancer · 2025Article
- Review
- Is Dermoscopy Destroying Clinical Dermatology?Dermatology practical & conceptual · 2025Article
- Rethinking Lymphadenectomy in Cutaneous Melanoma: From Routine Practice to Selective Indication: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Gene Mutation-Negative Malignant Melanoma in a Prepubertal Patient: A Clinical and Molecular Case Report.Genes · 2025Article
- Histopathological Subtypes of Cutaneous Melanoma: Prognostic and Molecular Implications.Cureus · 2025Review
- Early-Stage Melanoma Benchmark Dataset.Cancers · 2025Article
- Androgen-induced AR-BRD4 transcriptional regulatory complex promotes malignant proliferation of osteosarcoma cells.Cell death discovery · 2025Article
- Pulmonary metastases from malignant melanoma showing ground-glass opacity nodules.Japanese journal of radiology · 2025Article
- Review
- Epigenetic Therapies in Melanoma-Targeting DNA Methylation and Histone Modification.Biomedicines · 2025Review
- A Review of Melanoma Subtypes: Genetic and Treatment Considerations.Journal of surgical oncology · 2025Review
- [Dermoscopy of melanocytoma-groundbreaking or established knowledge].Dermatologie (Heidelberg, Germany) · 2024Article
- Polygenic Risk Score Improves Melanoma Risk Assessment in a Patient Cohort from the Veneto Region of Italy.Biology · 2024Article
- Nevi and Melanoma in Children: What to Do in Daily Medical Practice: Encyclopedia for Pediatricians and Family Doctors.Diagnostics (Basel, Switzerland) · 2024Review
- Review
- Utility and Micro-Costing Framework forDiagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The "multidimensional" World Health Organization (WHO) classification 2018 of melanocytic tumors encompasses nine melanoma pathways (seven of which for cutaneous melanoma) according to a progression model in which morphologically intermediate melanocytic tumors are cosidered as simulators and/or precursors to melanoma. These "intermediates" can be subclassified into: i) a "classical" subgroup (superficial/thin compound: dysplastic nevus), which is placed within the morphologic and molecular progression spectrum of classical (Clark's and McGovern's) melanoma subtypes (superficial spreading and, possibly, nodular); and ii) a "non-classical" subgroup (thick compound/dermal: "melanocytomas") whose genetic pathways diverge from classical melanoma subtypes. Such a progression model is aimed at giving a conceptual framework for a histopathological classification; however, routine clinicopathological practice strongly suggests that most melanomas arise
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.